Sensescape Competitors

The Oculus team at Facebook lets people experience anything, anywhere, with anyone through world-class VR hardware and software. With global departments dedicated to VR research, computer vision, haptics, social interaction, and more, Oculus is committed to driving the state of the art forward through relentless innovation. The Oculus suite of hardware currently includes: Rift, our high-end PC VR headset; Touch controllers, to bring your hands into virtual reality; and Gear VR, to bring the magic with you wherever you are—all powered by the Oculus Platform. Since being founded in 2012—and furthered through our acquisition by Facebook in 2014—Oculus has grown from the idea of a single headset to multiple headsets, a powerful platform, and a thriving ecosystem. Our developer community has built nearly a thousand games, apps, and experiences, all available on the Oculus Store. As we continue to grow the possibilities of the technology, we’re partnering with communities and nonprofits from around the world to drive social change and foster a positive impact. VR’s potential to connect the world is immense—and we’re just getting started. For more information, visit: http://oculus.com.

Immersion (NASDAQ: IMMR) is the world leading innovator of touch feedback technology, also known as haptics. The company provides haptic technology to create immersive and realistic experiences that enhance digital interactions on mobile devices. Immersion's technologies have been adopted in more than 3 billion digital devices that, along with mobile, include automotive, gaming, medical and consumer electronics. Headquartered in San Jose, California, the company’s offices worldwide provide services/support, licensing options and software to help industry-leading electronics companies create high-quality haptic experiences. Immersion is enabling people to touch, feel and engage with the digital world, making it much more personal, vivid, and meaningful. Learn more at www.immersion.com.

Cognito Therapeutics is a pioneer in non-invasive neuromodulation to treat neurodegenerative diseases and improve human cognitive performance. The company has completed multiple clinical studies demonstrating its investigational therapeutic has the potential to safely slow or stop cognitive decline and loss of brain volume in Alzheimer’s disease. Cognito has received FDA Breakthrough Device Designation for the treatment of Alzheimer’s disease and expects to start pivotal studies in 2022. The company’s technology was based on pioneering optogenetics research by scientific co-founders Professors Li-Huei Tsai and Ed Boyden at MIT.